U.S. Pharma Stock News

Guidewire Software Q2 2026 Earnings Snapshot Guidewire Software (GWRE) has put up another solid print for Q2 2026, with revenue at US$359.1 million and basic EPS of US$0.71, setting the tone for a cleaner run of profitability. The company has seen revenue move from US$289.5 million and basic EPS of US$0.45 loss in Q2 2025 to US$359.1 million and US$0.71 EPS in Q2 2026, while trailing 12 month EPS sits at US$2.24 on revenue of about US$1.3 billion, giving investors more visibility on earnings...

If you are wondering whether National Energy Services Reunited is still attractively priced after its recent run, you are not alone. This article is here to unpack the valuation story in a clear, practical way. The share price last closed at US$20.86, with a 1 year return of 163.4%, a 3 year return of 254.2%, and a year to date return of 32.1%. The stock has seen a 16.7% decline over the past 7 days and a 2.0% return over the past 30 days. Recent news flow around National Energy Services...

Illumina stock after recent performance Illumina (ILMN) has drawn fresh attention after a period where the share price has declined about 7% over the past month and roughly 3% over the past 3 months, despite a positive 1 year total return. See our latest analysis for Illumina. Short term momentum has faded for Illumina, with a 1 day share price decline of 2.82% and softer recent returns, even though the 1 year total shareholder return sits at 43.87%. If Illumina’s recent swings have you...

The FDA’s decision to lift the clinical hold on Intellia Therapeutics (NTLA) MAGNITUDE Phase 3 trial and the new hereditary angioedema data for lonvoguran ziclumeran have refocused attention on the company’s gene editing pipeline. See our latest analysis for Intellia Therapeutics. At a share price of $13.44, Intellia has seen a 39.85% 90 day share price return and a 45.93% year to date share price return. The 5 year total shareholder return of 79.49% and 3 year total shareholder return of...

BD (NYSE:BDX) received FDA 510(k) clearance for its Surgiphor 1000mL antimicrobial irrigation system designed for powered lavage, expanding its surgical solutions portfolio. The company also launched the BD Vacutainer Urine Complete Cup Kit, a three tube urine collection system intended to support more consistent sample quality and workflow efficiency. These back to back product milestones highlight ongoing activity in BD's medical and diagnostics franchises that could influence how...

In March 2026, Autohome Inc. reported past fourth-quarter and full-year 2025 results showing lower revenue and net income year-on-year, while also disclosing that it had repurchased 7,116,939 shares for US$184.50 million under its prior buyback plan. On the same day, the Board authorized a new US$200 million share repurchase program funded from existing cash, underlining management’s commitment to shareholder returns as Autohome advances its AI-driven, online-to-offline automotive service...

AGCO stock: recent move puts valuation in focus AGCO (AGCO) shares have been under pressure in the past week, with a 9.2% decline following a 2.9% drop in the latest session. This has put fresh attention on the agricultural equipment maker's current valuation and fundamentals. See our latest analysis for AGCO. That sharp 7 day share price return of negative 9.25% comes after a solid 90 day share price return of 17.69% and a 1 year total shareholder return of 21.86%. Recent momentum therefore...

Rigel Pharmaceuticals (RIGL) is back in focus after reporting fourth quarter and full year 2025 results, with revenue of US$69.8 million for the quarter and net income of US$268.07 million. See our latest analysis for Rigel Pharmaceuticals. Despite the strong Q4 and full year 2025 earnings, Rigel Pharmaceuticals' recent share price performance has been weak, with a 90 day share price return of 40.99% and a year to date share price return of 30.98%, while the 1 year total shareholder return of...

Jazz Pharmaceuticals reported record revenues for 2025 and highlighted strong Q4 results. The company completed regulatory filing for zanidatamab in gastroesophageal adenocarcinoma, positioning the therapy for potential approval and launch. Management emphasized ongoing expansion of its rare disease portfolio and upcoming clinical trial readouts. Shares of Jazz Pharmaceuticals (NasdaqGS:JAZZ) recently closed at $182.01, with the stock up 31.1% over the past year and 35.8% over three years...

If you are trying to figure out whether Tsakos Energy Navigation is attractively priced or not, this article will walk through what the current share price might be implying about the business. The stock most recently closed at US$34.75, with returns of 32.0% over 30 days, 58.7% year to date and 124.7% over the past year, alongside a 1.6% decline over the last week. Recent coverage around Tsakos Energy Navigation has focused on its role in the energy shipping sector and how investors are...

Recent share performance sets the stage Customers Bancorp (CUBI) has drawn fresh attention after a recent share pullback, with the stock down about 14% over the past month and roughly 5% over the past 3 months. See our latest analysis for Customers Bancorp. While the recent 14% one month share price pullback and 9.5% year to date share price decline may hint at fading short term momentum, the 34.3% one year total shareholder return and very large 195% three year total shareholder return show...

CoreWeave (NasdaqGS:CRWV) has been hit with a securities class action lawsuit alleging it overstated its ability to scale and downplayed delays tied to a single data center supplier. At the same time, the company is pursuing debt funded expansion, reporting soft near term revenue guidance, and ramping up large capital expenditures. At a share price of $72.99, CoreWeave is contending with a 7 day return of an 8.3% decline, a 30 day return of an 11.5% decline, and an 8.0% decline year to...

If you are wondering whether Marriott Vacations Worldwide is priced attractively right now, this article walks through what the current share price might be implying about its value. The stock closed at US$70.50 recently, with returns of 8.4% over the past week, 26.5% over the past month, 19.8% year to date, and 1.4% over the past year, alongside much weaker 3 and 5 year returns of 44.6% and 56.6% declines. These mixed returns mean some investors may see recent strength as a rebound, while...

Dutch Bros recently rolled out its Back to Cool menu nationwide, adding three nostalgic, limited-time drinks such as Brown Butter Chocolate Chip, Fruit Punch with a Sour Candy Straw and Kool Blue across more than 1,136 shops. This push into childhood-inspired flavors highlights how Dutch Bros is leaning into customization and nostalgia to deepen engagement with its predominantly younger, iced-drink-focused customer base. Next, we’ll examine how this nostalgic menu push and broader...

Healthpeak Properties (NYSE:DOC) reports progress on integrating a recent merger into its healthcare real estate platform. The company has shifted to an internal management structure, changing how it oversees its portfolio and corporate decisions. Healthpeak is preparing for a potential Janus Living IPO, aimed at surfacing value tied to its senior housing exposure. Healthpeak Properties focuses on healthcare real estate, including assets tied to senior housing, a segment closely watched as...

CleanSpark, Inc. recently reported unaudited operating results for February 2026, producing 568 bitcoin while progressing the acquisition of a second Texas campus with 300 megawatts of ERCOT-approved capacity. The company sold about 97% of its February bitcoin production to help fund a pivot toward AI and high-performance computing data centers, even as it reported an earnings per share loss of $1.35 in fiscal Q1 2026 versus analyst expectations of $0.26. With CleanSpark expanding into a 300...

In recent days, Jack Henry & Associates reported earnings and revenue that exceeded expectations, raised its fiscal 2026 guidance, increased its quarterly dividend to US$0.61 per share, and highlighted product wins such as Financial Crimes Defender’s selection by SELCO Community Credit Union and its addition to the ICBA Preferred Service Provider program. These results, alongside expanding digital asset capabilities through Stablecore’s integration into the Jack Henry Fintech Integration...

Northern Oil and Gas, Inc. recently reported its fourth-quarter and full-year 2025 results, showing higher revenue and total production alongside a quarterly net loss driven by a US$268,497,000 impairment of oil and gas assets. At the same time, the company affirmed its quarterly US$0.45 dividend, expanded its revolving credit facility commitments to US$1.80 billion, and issued detailed 2026 production guidance outlining both low- and high-activity development scenarios. Now we’ll examine...

SolarEdge Technologies (NasdaqGS:SEDG) reported strong fourth quarter results, highlighting operational improvements across the business. The company issued guidance for positive free cash flow, pointing to tighter cost control and improved execution. Management is targeting a return to profitability later this year, signaling a potential turnaround after previous challenges. SolarEdge focuses on solar inverters and related energy technologies, so its results often reflect broader trends in...

Civitas Resources, now part of SM Energy, recently saw SM Energy launch a cash tender offer of up to US$750 million for 8.375% senior notes due 2028 originally issued by Civitas, while also reporting full-year 2025 revenue of US$4,393 million and net income of US$561 million, both lower than the prior year. The combination of weaker annual earnings and SM Energy’s move to refinance inherited Civitas debt highlights how the merger is reshaping the company’s capital structure and cash flow...

Why Enovix Stock Is Back in Focus After Earnings and Rising Short Interest Enovix (ENVX) is drawing fresh attention after reporting record fourth quarter revenue, ongoing losses and cautious near term guidance, just as short interest has climbed to one of the highest levels among its peers. See our latest analysis for Enovix. Despite record Q4 revenue, Enovix’s 1 day share price return of 3.96% decline and 30 day share price return of 24.34% decline, alongside a 1 year total shareholder...

If you are looking at Old Republic International and wondering whether the current share price reflects its true worth, this article walks through the key numbers that can help you frame that question. The stock closed at US$41.82, with returns of 22.1% over 1 year and 176.2% over 5 years. The year-to-date move of 3.4% and the last 7 days at 2.4% lower show that the ride has not been perfectly smooth. Recent coverage of Old Republic International has focused on its position within the US...

What recent performance says about Weyerhaeuser With no single headline event driving attention to Weyerhaeuser (WY) today, investors are instead looking at the stock’s recent return pattern and fundamentals to gauge how the business is currently positioned. Over the past month, Weyerhaeuser’s share price shows an 8.24% decline, while the past 3 months reflect a 12.96% gain. The 1-year total return sits at a 17.98% decline, with a 3-year total return of an 11.06% decline and a 5-year total...

If you are looking at ANI Pharmaceuticals and wondering whether the current share price really reflects its value, this article will walk through the key numbers that matter. The stock last closed at US$74.04, with returns of 0.2% over 7 days, an 8.9% decline over 30 days, a 5.6% decline year to date, and gains of 22.1% over 1 year, 81.2% over 3 years, and 128.9% over 5 years. Recent news coverage has focused on ANI Pharmaceuticals in the context of broader interest in the specialty...